Skip to content

Samidorphan

Lybalvi (samidorphan) is a small molecule pharmaceutical. Samidorphan was first approved as Lybalvi on 2021-05-28. It is known to target delta-type opioid receptor, kappa-type opioid receptor, and mu-type opioid receptor. Lybalvi's patents are valid until 2032-02-13 (FDA).
Trade Name Lybalvi
Common Name Samidorphan
Indication
Drug Class Narcotic antagonists/agonists (morphinan derivatives)
Samidorphan
Get full access now